[go: up one dir, main page]

PE20090902A1 - Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos - Google Patents

Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos

Info

Publication number
PE20090902A1
PE20090902A1 PE2008001275A PE2008001275A PE20090902A1 PE 20090902 A1 PE20090902 A1 PE 20090902A1 PE 2008001275 A PE2008001275 A PE 2008001275A PE 2008001275 A PE2008001275 A PE 2008001275A PE 20090902 A1 PE20090902 A1 PE 20090902A1
Authority
PE
Peru
Prior art keywords
antimittic
combination
halo
alkyl
kinase inhibitor
Prior art date
Application number
PE2008001275A
Other languages
English (en)
Inventor
Andrea Dawn Basso
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40305124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090902(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20090902A1 publication Critical patent/PE20090902A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

REFERIDO A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN AGENTE ANTIMITOTICO SELECCIONADO DEL GRUPO QUE CONSISTE DE: TAXANO, PACLITAXEL, UN COMPUESTO DE FORMULA (A) ENTRE OTROS. DONDE EL ANILLO Y ES ARILO DE 5 A 6 MIEMBROS O UN HETEROARILO DE 5 O 6 MIEMBROS FUSIONADO COMO SE INDICA EN LA FORMULA A; W ES N O C(R12), DONDE R12 ES H, HALO, ALQUILO, ENTRE OTROS; X ES N O N-OXIDO; Z ES S, S(=O) O S(=O)2; R1 ES H, ALQUILO, HALO, ENTRE OTROS; R2 ES H, HALO, ARILO, ENTRE OTROS; R3 ES ALQUILO, CICLOALQUILO, HETEROCICLILO, ENTRE OTROS; Y B) UN INHIBIDOR DE AURORA QUINASA.TAL COMO (E), DONDE R ES H, CN, CICLOALQUILO, ENTRE OTROS; R1, R2 Y R3 SON H, ARILO, HETEROARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (i), (ii), (iii), ENTRE OTROS. TAMBIEN SE REFIERE A UN METODO DE PREPARACION. DICHO COMPUESTO ES INHIBIDOR DEL CRECIMIENTO CELULAR Y ES UTIL EN EL TRATAMIENTO DEL CANCER
PE2008001275A 2007-07-31 2008-07-30 Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos PE20090902A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95308707P 2007-07-31 2007-07-31
US2398508P 2008-01-28 2008-01-28

Publications (1)

Publication Number Publication Date
PE20090902A1 true PE20090902A1 (es) 2009-07-25

Family

ID=40305124

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001275A PE20090902A1 (es) 2007-07-31 2008-07-30 Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos

Country Status (17)

Country Link
US (1) US20100249030A1 (es)
EP (1) EP2182986A2 (es)
JP (1) JP2010535201A (es)
KR (1) KR20100042287A (es)
CN (1) CN101808666A (es)
AR (1) AR068048A1 (es)
AU (1) AU2008282885A1 (es)
BR (1) BRPI0814874A2 (es)
CA (1) CA2694218A1 (es)
CL (1) CL2008002224A1 (es)
CO (1) CO6331446A2 (es)
EC (1) ECSP109918A (es)
MX (1) MX2010001340A (es)
PE (1) PE20090902A1 (es)
RU (1) RU2010106878A (es)
TW (1) TW200911241A (es)
WO (1) WO2009017701A2 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080928A1 (es) * 2006-10-31 2008-08-15 Schering Corp Derivados de anilinopiperazina como inhibidores de proteina quinasa
MX2009004785A (es) * 2006-10-31 2009-06-05 Schering Corp Amidas 2-aminotiazol-4-carboxilicas como inhibidores de proteina quinasa.
WO2009097233A1 (en) * 2008-01-28 2009-08-06 Schering Corporation Imidazopyrazines as protein kinase inhibitors
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
WO2011025706A2 (en) * 2009-08-26 2011-03-03 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
US8435976B2 (en) * 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
US20120220581A1 (en) 2009-10-30 2012-08-30 Janssen-Cilag, S.A. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2576560B1 (en) 2010-06-01 2015-09-30 Bayer Intellectual Property GmbH Substituted imidazopyrazines
JP2013545776A (ja) * 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
MX339243B (es) 2011-02-03 2016-05-18 Vtv Therapeutics Llc Derivados fusionados sustituidos de imidazol, composiciones farmaceuticas y metodos de uso de los mismos.
EP2723744B1 (en) 2011-06-27 2016-03-23 Janssen Pharmaceutica, N.V. 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
CN103204824B (zh) * 2012-01-12 2015-04-08 清华大学深圳研究生院 2-氨基噻唑-4-酰胺类衍生物及其制备方法与应用
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2657540C2 (ru) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств
ES2607184T3 (es) 2012-07-09 2017-03-29 Janssen Pharmaceutica, N.V. Inhibidores de la enzima fosfodiesterasa 10
EP2909203A4 (en) * 2012-10-22 2016-04-06 Egenix Inc COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES OR DISEASES RELATED TO EIF4E MALFUNCTION
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
EA035929B1 (ru) * 2013-01-15 2020-09-02 Инсайт Холдингс Корпорейшн ТИАЗОЛКАРБОКСАМИДЫ И ПИРИДИНКАРБОКСАМИДЫ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Pim-КИНАЗЫ
SG11201601259YA (en) 2013-08-23 2016-03-30 Incyte Corp Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RS59534B1 (sr) 2014-02-13 2019-12-31 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
PH12020552066A1 (en) 2014-02-13 2022-05-11 Incyte Corp Cyclopropylamines as lsd1 inhibitors
ES2672797T3 (es) 2014-02-13 2018-06-18 Incyte Corporation Ciclopropilaminas como inhibidores de LSD1
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9321766B1 (en) 2014-10-06 2016-04-26 Allergan, Inc. Kinase inhibitors
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
WO2016115272A1 (en) 2015-01-13 2016-07-21 Vanderbilt University Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP3626720A1 (en) 2015-04-03 2020-03-25 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
MX389824B (es) 2015-08-12 2025-03-20 Incyte Holdings Corp Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1).
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
IL262488B (en) 2016-04-22 2022-08-01 Incyte Corp lsdi inhibitor formulations
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
KR102584855B1 (ko) * 2018-06-26 2023-10-05 케이피씨 파마슈티컬스 인코포레이티드 벤즈이미다졸 유도체 및 idh1 억제제로서의 이의 용도
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CN113874015B (zh) 2018-12-21 2024-05-24 细胞基因公司 Ripk2的噻吩并吡啶抑制剂
AU2021280893A1 (en) 2020-05-08 2023-01-05 Halia Therapeutics, Inc. Inhibitors of NEK7 kinase
US20240158394A1 (en) 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors
WO2024088192A1 (en) * 2022-10-26 2024-05-02 Js Innopharm (Suzhou) Ltd. An aurora a inhibitor for use in treatments of cancers
CN116987041A (zh) * 2023-08-02 2023-11-03 河北科技大学 一种转移氢化法制备5-(2-氨基-4-氯苯基)四氮唑的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050081A1 (es) * 2002-09-23 2005-03-01 Schering Corp Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
CA2531142A1 (en) * 2003-07-03 2005-01-13 Cambridge University Technical Services Ltd Use of aurora kinase inhibitors for reducing the resistance of cancer cells
US7608643B2 (en) * 2005-03-09 2009-10-27 Schering Corporation Compounds for inhibiting KSP kinesin activity
CA2599901A1 (en) * 2005-03-09 2006-09-21 Schering Corporation Compounds for inhibiting ksp kinesin activity
CN101370811A (zh) * 2005-11-10 2009-02-18 先灵公司 作为蛋白激酶抑制剂的咪唑并吡嗪化合物

Also Published As

Publication number Publication date
RU2010106878A (ru) 2011-09-10
US20100249030A1 (en) 2010-09-30
KR20100042287A (ko) 2010-04-23
CO6331446A2 (es) 2011-10-20
MX2010001340A (es) 2010-06-02
BRPI0814874A2 (pt) 2019-09-24
CA2694218A1 (en) 2009-02-05
JP2010535201A (ja) 2010-11-18
AR068048A1 (es) 2009-11-04
TW200911241A (en) 2009-03-16
ECSP109918A (es) 2010-02-26
CL2008002224A1 (es) 2009-07-17
AU2008282885A1 (en) 2009-02-05
WO2009017701A3 (en) 2009-05-07
EP2182986A2 (en) 2010-05-12
WO2009017701A2 (en) 2009-02-05
CN101808666A (zh) 2010-08-18

Similar Documents

Publication Publication Date Title
PE20090902A1 (es) Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos
PE20091414A1 (es) FURO [3,2-c] PIRIDINA Y TIENO [3,2-c] PIRIDINAS
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20090511A1 (es) Imidazopiridinonas
PE20090905A1 (es) Compuestos heterociclicos de amidas como inhibidores de la proteincinasa
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
PE20050081A1 (es) Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
ECSP088563A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
PA8632701A1 (es) Compuestos terapeuticos
PE20110153A1 (es) Derivados de piridazina como inhibidores de smo
PE20090772A1 (es) Derivados de bencimidazol
PE20140244A1 (es) Composicion farmaceutica, metodos de tratamiento y usos de la misma
ATE522249T1 (de) Organische verbindungen
UY28936A1 (es) Grupo de compuestos benzoil-amino-heterociclilo y composiciones farmaceuticas que los comprenden, utiles para tratamiento de enfermedades mediadas por glucoquinasa (gq)
PE20090156A1 (es) Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
AR077817A1 (es) Derivados de 1, 2, 4-triazol y su uso como pesticidas
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
PE20091349A1 (es) Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp
PE20070621A1 (es) 2-amino-7,8-dihidro-6h-pirido(4,3-d)pirimidina-5-onas
AR062258A1 (es) Compuestos heterociclicos condensados de tieno-pirrol, composiciones farmaceuticas que los contienen y usos para el tratamiento de infecciones por hcv

Legal Events

Date Code Title Description
FC Refusal